Clinical trial
Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX
NCT00381862 · OHSU Knight Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00381862 |
|---|---|
| Title | Phase II Trial of Aprepitant & Palonosetron for CINV Prevention w FOLFOX |
| Official title | A Multi-Center, Trial to Evaluate the Efficacy & Tolerability of Aprepitant and Palonosetron for the Prevention of CINV in Colorectal Cancer (CRC) Patients Receiving FOLFOX |
| Lead sponsor | OHSU Knight Cancer Institute, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Colorectal Cancer, Nausea and Vomiting |
| Intervention type | Drug, Procedure |
| Interventions | aprepitant, dexamethasone, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin, palonosetron hydrochloride, quality-of-life assessment |
| Enrollment | 54 |
| Start date | Jun 1, 2006 |
| Primary completion | Mar 1, 2008 |
| Completion | Jul 1, 2008 |
| First posted | Sep 28, 2006 |
| Last update posted | Jun 12, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: